Ben Fidler
Lead Editor | @BentheFidlerBen is a lead editor for BioPharma Dive. He is a veteran business journalist with more than 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
851 articles by Ben Fidler
-
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
Feb. 27, 2026 -
Sarepta CEO Doug Ingram to retire, with company at a crossroads
Feb. 26, 2026 -
Novo, searching for a spark, spotlights new data for three-pronged obesity drug
Feb. 24, 2026 -
Merck to split cancer, specialty drug businesses in leadership shakeup
Feb. 23, 2026 -
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
Feb. 23, 2026 -
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Feb. 20, 2026 -
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
Feb. 7, 2026 -
Novo, Lilly sputter as Hims launches knockoff GLP-1 pill
Feb. 5, 2026 -
GSK walks away from pioneering Wave RNA editing drug
Feb. 2, 2026 -
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
Jan. 30, 2026 -
The biopharma industry outlook on 2026: Optimism and tension
Jan. 29, 2026 -
China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
Jan. 26, 2026 -
Biotech investor Cormorant secures $150M for another SPAC deal
Jan. 26, 2026 -
AbbVie pledges $100B to US production in drug pricing deal with Trump
Jan. 13, 2026 -
Eikon, a high-profile startup led by Merck vets, seeks an IPO
Jan. 11, 2026 -
Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies
Jan. 9, 2026 -
Novo launches Wegovy pill; Argenx to swap CEOs
Jan. 5, 2026 -
Radiopharmaceutical specialist Aktis seeks an IPO
Dec. 22, 2025 -
Cytokinetics set to battle Bristol Myers as FDA approves heart drug
Dec. 21, 2025 -
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
Dec. 18, 2025 -
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease
Dec. 15, 2025 -
Sobi snaps up gout drug in $950M deal for startup Arthrosi
Dec. 14, 2025 -
Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar
Dec. 8, 2025 -
Richard Pazdur, FDA drug czar, to retire from agency
Dec. 2, 2025 -
Belite continues ascent as Stargardt drug hits mark in late-stage trial
Dec. 1, 2025
